TTK promotes HER2 + breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis.

IF 2.7 3区医学 Q3 ONCOLOGY

Journal of Cancer Research and Clinical Oncology Pub Date : 2024-11-26 DOI:10.1007/s00432-024-06021-9

Shaolin Zhang, Hua Ding, Yongfen Deng, Yu Ren, Fulin Zhou, Qian Zhang, Shu Liu

{"title":"TTK promotes HER2 + breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis.","authors":"Shaolin Zhang, Hua Ding, Yongfen Deng, Yu Ren, Fulin Zhou, Qian Zhang, Shu Liu","doi":"10.1007/s00432-024-06021-9","DOIUrl":null,"url":null,"abstract":"Background: HER2 + breast cancer is a malignant neoplasm with a high degree of aggressiveness and therapeutic challenge. In recent years, studies have indicated a strong correlation between TTK and various tumors, though its role in HER2 + BRCA remains unclear.Objectives: Studying the biological function of the TTK gene in HER2 + BRCA and its resistance to targeted therapy it provides new ideas for targeted drug research.Methods: TTK was knocked down by small interfering RNA transfection, and its biological function in HER2 + BRCA cells was verified, and its mechanism of action was verified by RT-PCR and Western blot.Results: The study demonstrated that TTK promoted cell proliferation and migration by activating the Akt/mTOR pathway in HER2 + breast cancer and enhanced the drug sensitivity of BRCA cell lines SKBR3 and BT474 to pyrotinib, in addition, knockdown of TTK induced apoptosis and arrested cells in G1 phase.Conclusion: Which implies that TTK is an oncogene in HER2 + BRCA and is a valuable research target.","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"512"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599621/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-024-06021-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: HER2 + breast cancer is a malignant neoplasm with a high degree of aggressiveness and therapeutic challenge. In recent years, studies have indicated a strong correlation between TTK and various tumors, though its role in HER2 + BRCA remains unclear.

Objectives: Studying the biological function of the TTK gene in HER2 + BRCA and its resistance to targeted therapy it provides new ideas for targeted drug research.

Methods: TTK was knocked down by small interfering RNA transfection, and its biological function in HER2 + BRCA cells was verified, and its mechanism of action was verified by RT-PCR and Western blot.

Results: The study demonstrated that TTK promoted cell proliferation and migration by activating the Akt/mTOR pathway in HER2 + breast cancer and enhanced the drug sensitivity of BRCA cell lines SKBR3 and BT474 to pyrotinib, in addition, knockdown of TTK induced apoptosis and arrested cells in G1 phase.

Conclusion: Which implies that TTK is an oncogene in HER2 + BRCA and is a valuable research target.

查看原文本刊更多论文

TTK 通过调节 Akt/mTOR 轴，促进 HER2 + 乳腺癌细胞迁移、凋亡和对靶向治疗的耐受性。

研究背景HER2+乳腺癌是一种侵袭性强、治疗难度大的恶性肿瘤。近年来，研究表明 TTK 与多种肿瘤之间存在密切联系，但其在 HER2 + BRCA 中的作用仍不明确：研究 TTK 基因在 HER2 + BRCA 中的生物学功能及其对靶向治疗的耐药性，为靶向药物研究提供新思路：方法：通过小干扰RNA转染敲除TTK，验证其在HER2 + BRCA细胞中的生物学功能，并通过RT-PCR和Western blot验证其作用机制：研究表明，TTK通过激活Akt/mTOR通路促进了HER2+乳腺癌细胞的增殖和迁移，并增强了BRCA细胞株SKBR3和BT474对吡罗替尼的药物敏感性，此外，敲除TTK可诱导细胞凋亡并使细胞停滞在G1期：结论：这意味着TTK是HER2 + BRCA的致癌基因，是一个有价值的研究靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cancer Research and Clinical Oncology 医学-肿瘤学

CiteScore

4.00

自引率

2.80%

发文量

577

审稿时长

2 months

期刊介绍： The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses. The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.